Aminacrine

Aminacrine

SCHEMBL1040669

N=c1c2ccccc2[nH]c2ccccc12

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.68
GPR3 P46089 2/20 0.68
HSD17B10 Q99714 2/20 0.68
KDM4E B2RXH2 4/20 0.56
HPGD P15428 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
AHR P35869 2/20 0.56
LMNA P02545 2/20 0.56
GLA P06280 1/20 0.56
GAA P10253 1/20 0.56
HTT P42858 1/20 0.56
ATM Q13315 1/20 0.56
KIF11 P52732 4/20 0.46
GABRP O00591 2/20 0.46
GABRD O14764 2/20 0.46
GABRA1 P14867 2/20 0.46
GABRB1 P18505 2/20 0.46
GABRG2 P18507 2/20 0.46
GABRB3 P28472 2/20 0.46
GABRA5 P31644 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbazole SCHEMBL7650 0.82 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EHPGD
Carbazole SCHEMBL370524 0.82 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EHPGD
Carbazole SCHEMBL30209164 0.82 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EHPGD
Carbazole SCHEMBL29627417 0.82 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EHPGD
Carbazole SCHEMBL30761795 0.82 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EHPGD
Carbazole SCHEMBL29355407 0.82 ALDH1A1 (1.00) ALDH1A1GPR3HSD17B10KDM4EHPGD
SCHEMBL24058091 0.80 GAA (0.64) ALDH1A1GPR3HSD17B10KDM4EHPGD
Carbazole SCHEMBL25328075 0.79 ALDH1A1 (0.93) ALDH1A1GPR3HSD17B10KDM4EHPGD
Carbazole SCHEMBL25327723 0.79 ALDH1A1 (0.93) ALDH1A1GPR3HSD17B10KDM4EHPGD
Carbazole SCHEMBL22712375 0.79 ALDH1A1 (0.93) ALDH1A1GPR3HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263755-A1 STABILIZATION OF ACETAMINOPHEN IN AQUEOUS SOLUTION NOSTRUM PHARMACEUTICALS, LLC (US) 2023-08-24 US disclosed
EP-3519386-B1 NOVEL PI-CONJUGATED MATERIALS, METHODS FOR PREPARING SAME AND USES THEREOF AS SEMICONDUCTORS DEGBIA MARTIAL (FR) 2023-03-29 EP disclosed
US-9943479-B2 Injectable liquid paracetamol formulation GENFARMA LABORATORIO S.L. (ES) 2018-04-17 US disclosed
US-9943492-B2 Injectable liquid paracetamol formulation GENFARMA LABORATORIO S.L. (ES) 2018-04-17 US disclosed
EP-2609639-B1 USE OF ZWITTERIONIC MOLECULES FOR FORMING A HOLE OR ELECTRON TRANSPORT LAYER CENTRE NAT RECH SCIENT (FR) 2016-10-05 EP disclosed
US-20160199325-A1 INJECTABLE LIQUID PARACETAMOL FORMULATION ALTAN PHARMACEUTICALS S.A.U. (ES) 2016-07-14 US disclosed
EP-2277546-B1 Stable ready to use injectable paracetamol formulation UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB S A (GR) 2015-07-15 EP disclosed
US-9006488-B1 Solvent free synthesis of acetaminophen AMIN MUHAMMAD (PK) 2015-04-14 US disclosed
US-8877817-B2 Stable ready to use injectable paracetamol formulation TSETI IOULIA (GR) 2014-11-04 US disclosed
US-20130210922-A1 STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION UNIPHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2013-08-15 US disclosed
US-20120190750-A1 STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2012-07-26 US disclosed
CN-102600068-A Stable ready-to-use injectable paracetamol formulation LINCON PHARMACEUTICAL CRAINTSIRTIS PHARMACEUTICAL LAB S A 2012-07-25 CN disclosed
EP-2389923-A1 Stable ready to use injectable paracetamol formulation Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) 2011-11-30 EP disclosed
WO-2011144335-A1 STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2011-11-24 WO disclosed
WO-2011071400-A1 METHOD AND COMPOSITION FOR PREPARING STABLE LIQUID FORMULATIONS OF PARACETAMOL TECNIMEDE - SOCIEDADE TÉCNICO-MEDICINAL, S.A. (PT) 2011-06-16 WO disclosed
EP-2277546-A1 Stable ready to use injectable paracetamol formulation Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) 2011-01-26 EP disclosed
EP-2100596-A2 Injectable liquid paracetamol formulation Genfarma Laboratorio S.L. (ES) 2009-09-16 EP disclosed
US-20090215903-A1 Injectable Liquid Paracetamol Formulation GES GENERICOS ESPAÑOLES LABORATORIO, S.A (ES) 2009-08-27 US disclosed
EP-1889607-B1 Injectable liquid paracetamol formulation GENFARMA LAB S L (ES) 2009-06-03 EP disclosed
EP-1889607-A1 Injectable liquid paracetamol formulation Genfarma Laboratorio S.L. (ES) 2008-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160199325-A1 INJECTABLE LIQUID PARACETAMOL FORMULATION CYP3A5, CYP3A4, CYP2C9 ALDH1A1 444/4885GPR3 1767/4885HSD17B10 1371/4885
US-20090215903-A1 Injectable Liquid Paracetamol Formulation CYP3A7, CYP4F3, CYP3A5 ALDH1A1 276/4885GPR3 3071/4885HSD17B10 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.